IRulya Therapeutics Inc. (NASDAQ:IRLA)
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$92.5M
- Net margin
- —
Little or no net debt.
- Total debt
- $0
- Cash
- $116.0M
- Debt / equity
- 0.00
Comfortably covers what is due within a year.
- Current assets
- $123.4M
- Current liabilities
- $8.5M
- Current ratio
- 14.52
Consumes cash and must keep raising it.
- Operating cash flow
- -$46.9M
- Free cash flow
- -$47.0M
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 6.1M
- Share growth (1y)
- 2527.3%
- Cash runway
- 30 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
IRLA Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | $0.00 | $36.00 K | $0.00 | $0.00 | $35.00 K | $0.00 |
| Gross Profit | $0.00 | -$36.00 K | $0.00 | $0.00 | -$35.00 K | $0.00 |
| SG&A Expense | $16.63 M | $4.27 M | $3.63 M | $3.28 M | $3.34 M | $4.79 M |
| R&D Expense | $5.46 M | $6.84 M | $12.60 M | $8.08 M | $6.55 M | $8.14 M |
| Operating Expenses | $79.78 M | $11.08 M | $19.35 M | $13.43 M | $9.86 M | $14.86 M |
| Operating Income | -$79.78 M | -$11.11 M | -$19.35 M | -$13.43 M | -$9.89 M | -$14.86 M |
| Pretax Income | -$75.41 M | $30.57 M | -$36.31 M | -$13.49 M | -$15.98 M | -$14.98 M |
| Tax Provision | $75.00 K | -$5.34 M | $3.15 M | -$46.00 K | $67.00 K | $47.00 K |
| Net Income | -$75.49 M | $35.91 M | -$39.46 M | -$13.44 M | -$16.05 M | -$15.03 M |
| EPS (Basic) | -$12.31 | $143.40 | -$150.00 | -$50.00 | -$68.00 | -$68.00 |
| EPS (Diluted) | -$12.31 | $143.40 | -$150.00 | -$50.00 | -$68.00 | -$68.00 |
| Shares Outstanding | 6.13 M | 250.49 K | 250.49 K | 269.76 K | 233.43 K | 219.71 K |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.